Qu Biologics Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Private

  • Employees
  • 23

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $291K

  • Investors
  • 10

Qu Biologics General Information

Description

Developer of site-specific immunotherapy designed to restore the body's normal immune function to treat cancer and other immune-related diseases. The company's immunotherapy utilizes built-in knowledge to direct an activated innate immune response to specific organs or tissues to respond productively to any pathology that may be present at that body site, enabling medical researchers to develop a therapy that can activate and train the human immune system to fight cancer and other diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 4475 Wayburne Drive
  • Suite 305
  • Burnaby, British Columbia V5G 4X4
  • Canada
+1 (604) 000-0000

Qu Biologics Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Qu Biologics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
14. Grant 14-Nov-2023 $291K 000.00 Completed Clinical Trials - Phase 2
13. Grant 17-Oct-2022 00.000 000.00 Completed Clinical Trials - Phase 2
12. Later Stage VC 21-Mar-2022 0000 000.00 Completed Clinical Trials - Phase 2
11. Grant 23-Jun-2021 00.000 000.00 Completed Clinical Trials - Phase 2
10. Later Stage VC 09-Dec-2020 000 000.00 00000 Completed Clinical Trials - Phase 2
9. Later Stage VC 02-Aug-2019 000.00 Completed Clinical Trials - Phase 2
8. Angel (individual) 04-Jun-2018 000.00 000.00 Completed Clinical Trials - Phase 2
7. Angel (individual) 12-Apr-2016 00.000 000.00 Completed Clinical Trials - Phase 2
6. Grant 06-Apr-2016 $182K $17.1M Completed Clinical Trials - Phase 2
5. Angel (individual) 23-Dec-2015 $2.58M $17.1M Completed Clinical Trials - Phase 1
To view Qu Biologics’s complete valuation and funding history, request access »

Qu Biologics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of site-specific immunotherapy designed to restore the body's normal immune function to treat cancer and other
Drug Discovery
Burnaby, Canada
23 As of 2024
000.00
0000000000 000.00

000000

in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint o
0000000000000
Gaithersburg, MD
00 As of 0000
00000
00000000 00000

000000

tur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna
0000 000000000
Newark, CA
0 As of 0000
000.00
00000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Qu Biologics Competitors (30)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NexImmune Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
Cellerant Therapeutics Venture Capital-Backed Newark, CA 0 000.00 00000000000 000.00
CytImmune Sciences Venture Capital-Backed Rockville, MD 0 000.00 0000000000 0 000.00
Kite Pharma Formerly VC-backed Santa Monica, CA 0000 00000 000000&0 00000
TScan Therapeutics Formerly VC-backed Waltham, MA 000 00000 00000000 00000
You’re viewing 5 of 30 competitors. Get the full list »

Qu Biologics Patents

Qu Biologics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022246300-A1 Perioperative innate immune priming in cancer therapy Pending 24-Mar-2021 000000000
CA-3212380-A1 Perioperative innate immune priming in cancer therapy Pending 24-Mar-2021 000000000
EP-4313176-A1 Perioperative innate immune priming in cancer therapy Pending 24-Mar-2021 000000000
EP-3735265-A4 Innate targeting of adoptive cellular therapies Pending 03-Jan-2018 000000000
EP-3735265-A1 Innate targeting of adoptive cellular therapies Pending 03-Jan-2018 A61K35/17
To view Qu Biologics’s complete patent history, request access »

Qu Biologics Executive Team (11)

Name Title Board Seat Contact Info
Harold Gunn MD Co-Founder, Chief Executive Officer, President & Board Member
Ky Quang Controller
Rob Freeman Co-Founder
Ted Steiner MD Co-Chief Medical Officer
Andrew Rae Chief Business Officer
You’re viewing 5 of 11 executive team members. Get the full list »

Qu Biologics Board Members (8)

Name Representing Role Since
Foster Coulson Integro Cap Board Member 000 0000
Harold Gunn MD Qu Biologics Co-Founder, Chief Executive Officer, President & Board Member 000 0000
Julia Levy Ph.D Self Board Member 000 0000
Karn Manhas Qu Biologics Board Member 000 0000
Marc Lambiotte Self Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Qu Biologics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Qu Biologics Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Canadian Institutes of Health Research Asset Manager 000 0000 000000 0
Integro Cap Venture Capital Minority 000 0000 000000 0
NRC-IRAP Government 000 0000 000000 0
Curitas Ventures Venture Capital Minority 000 0000 000000 0
Harmonix Fund Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »